ArticleJCO precision oncology2023

Marked Response to Larotrectinib in Pelvic Spindle Cell Sarcoma With Concurrent TPM3-NTRK1 Fusion and CDK4/MDM2 Amplification: A Case Report.

Wen-Kuan Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.